ttr-3 Antibody
Description
Key Antibodies Targeting Pathogenic TTR
The following antibodies show specificity for misfolded or aggregated TTR, which is critical in amyloidosis treatment:
Functional Validation of Anti-TTR Antibodies
-
NI301A: Demonstrated selective binding to ATTR in cardiac tissues from ATTR-CM patients. Ex vivo experiments showed macrophage-mediated clearance of ATTR deposits .
-
RT24: Reduced non-fibrillar TTR deposits in gastrointestinal tracts of FAP model rats and inhibited fibrillation in vitro .
Unresolved Questions and Future Directions
-
No antibody labeled "ttr-3" is currently described in peer-reviewed literature or commercial catalogs.
-
Hypothetically, a "ttr-3" antibody might target a distinct conformational epitope (e.g., β-strand interfaces) or oligomeric TTR species.
-
Further studies are needed to map all cryptic epitopes and optimize antibody pharmacokinetics for clinical use.
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
